These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25191727)

  • 1. Clinical risk factors of thrombosis in patients with Ph-negative myeloproliferative neoplasms, who had experienced radiation exposure due to the Chornobyl accident.
    Mishcheniuk OY; Klymenko SV
    Probl Radiac Med Radiobiol; 2013; (18):232-9. PubMed ID: 25191727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine.
    Mishcheniuk OY; Kostukevich OM; Dmytrenko IV; Sholoyko VV; Prokopenko IM; Martina ZV; Pilipenko GV; Klymenko SV
    Exp Oncol; 2013 Sep; 35(3):202-6. PubMed ID: 24084459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of hereditary thrombophilia to increasing the frequency of thrombosis in patients with Ph negative myeloproliferative neoplasms, including the victims from the Chornobyl accident.
    Mishcheniuk OY; Shkarupa VM; Kostukevich OM; Neumerzhitcka LV; Kravchenko SM; Klymenko SV
    Probl Radiac Med Radiobiol; 2016 Dec; 21():291-311. PubMed ID: 28027559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.
    Ball S; Thein KZ; Maiti A; Nugent K
    J Thromb Thrombolysis; 2018 May; 45(4):516-528. PubMed ID: 29404876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
    Mahjoub S; Baccouche H; Sahnoun M; Kaabi H; Manai Z; Slama H; Ben Romdhane N
    Tunis Med; 2015 Jul; 93(7):474-7. PubMed ID: 26757507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms.
    Caramazza D; Caracciolo C; Barone R; Malato A; Saccullo G; Cigna V; Berretta S; Schinocca L; Quintini G; Abbadessa V; Di Raimondo F; Siragusa S
    Ann Hematol; 2009 Oct; 88(10):967-71. PubMed ID: 19214510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of laboratory hematological parameters for thromboses development in patients with spontaneous and radiation associated Ph negative myeloproliferative neoplasms.
    Mishcheniuk OY; Klymenko SV
    Probl Radiac Med Radiobiol; 2015 Dec; 20():376-98. PubMed ID: 26695916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CONTRIBUTION OF THE G1691A ALLELE CARRYING OF THE COAGULATION FACTOR V GENE TO THE DEVELOPMENT OF THROMBOSES IN RADIATION-EXPOSED PATIENTS WITH REACTIVE CHANGES IN PERIPHERAL BLOOD.
    Mishcheniuk OY; Kostiukevych OM; Benkovska LK; Kravchenko OM; Klymenko SV
    Probl Radiac Med Radiobiol; 2020 Dec; 25():502-515. PubMed ID: 33361857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms.
    Krečak I; Gverić-Krečak V; Lapić I; Rončević P; Gulin J; Fumić K; Krečak F; Holik H; Duraković N
    Acta Clin Belg; 2021 Feb; 76(1):32-39. PubMed ID: 31455178
    [No Abstract]   [Full Text] [Related]  

  • 12. High Level of Circulating Microparticles in Patients with BCR/ABL Negative Myeloproliferative Neoplasm - a Pilot Study.
    Aswad MH; Kissová J; Rihova L; Zavrelova J; Ovesná P; Penka M
    Klin Onkol; 2019; 32(2):109-116. PubMed ID: 30995850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women.
    Leal AD; Thompson CA; Wang AH; Vierkant RA; Habermann TM; Ross JA; Mesa RA; Virnig BA; Cerhan JR
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):151-7. PubMed ID: 26564251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH).
    Appelmann I; Kreher S; Parmentier S; Wolf HH; Bisping G; Kirschner M; Bergmann F; Schilling K; Brümmendorf TH; Petrides PE; Tiede A; Matzdorff A; Griesshammer M; Riess H; Koschmieder S
    Ann Hematol; 2016 Apr; 95(5):707-18. PubMed ID: 26916570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evaluation of the relevance of thrombin generation and procoagulant activity in thrombotic risk assessment in BCR-ABL-negative myeloproliferative neoplasm patients.
    Baccouche H; Ben Jemaa M; Chakroun A; Chadi S; Mahjoub S; Sfar I; Gorgi Y; Ben Romdhane N
    Int J Lab Hematol; 2017 Oct; 39(5):502-507. PubMed ID: 28497580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of multiple myeloma among cleanup workers of the Chornobyl accident and their survival.
    Bazyka D; Gudzenko N; Dyagil I; Trotsiuk N; Gorokh E; Fedorenko Z; Chumak V; Bakhanova E; Ilienko I; Romanenko A
    Exp Oncol; 2016 Dec; 38(4):267-271. PubMed ID: 28230831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic.
    Barbui T; De Stefano V
    Curr Hematol Malig Rep; 2021 Oct; 16(5):455-463. PubMed ID: 34586561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms.
    Falanga A; Marchetti M; Schieppati F
    Hamostaseologie; 2021 Feb; 41(1):48-57. PubMed ID: 33588455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Inflammation Parameters in Philadelphia Negative Chronic Myeloproliferative Neoplasia Patients.
    Hacibekiroglu T; Akinci S; Basturk A; inal B; Guney T; Bakanay SM; Dilek I
    Asian Pac J Cancer Prev; 2015; 16(13):5159-62. PubMed ID: 26225646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.